In patients with breast cancer, denosumab has recently been shown to reduce the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors and is currently being studied for any effect on prolonging bone metastasis free survival in women with early-stage breast cancer who are at high risk for disease recurrence (Gnant et al., 2015). Here, CYP19A1 is linked to breast cancer.